Basit öğe kaydını göster

dc.contributor.authorÇiftçiler, Rafiye
dc.contributor.authorGöker, Hakan
dc.contributor.authorDemiroğlu, Haluk
dc.contributor.authorAladağ, Elifcan
dc.contributor.authorAksu, Salih
dc.contributor.authorHaznedaroğlu, İbrahim Celalettin
dc.contributor.authorSayınalp, Nilgün
dc.contributor.authorÖzcebe, Osman
dc.contributor.authorTekin, Fatma
dc.contributor.authorBüyükaşık, Yahya
dc.date.accessioned2021-06-03T05:20:10Z
dc.date.available2021-06-03T05:20:10Z
dc.date.issued2019
dc.identifier.issn1300-7777
dc.identifier.urihttp://dx.doi.org/10.4274/tjh.galenos.2019.2018.0220
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516104/
dc.identifier.urihttp://hdl.handle.net/11655/23998
dc.description.abstractObjective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens could have different clinical outcomes. This purpose of this study was to assess the long-term outcome of MAC versus RIC regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic HSCT. Materials and Methods: We retrospectively compared long-term outcomes with MAC and RIC regimens in patients with AML who underwent allo-HSCT at our tertiary transplantation center. Results: We analyzed survival outcomes after MAC-HSCT versus RICHSCT among 107 adult patients with AML diagnosed from 2001 through 2017. Of those, 44 patients underwent a MAC regimen, whereas 63 patients received a RIC regimen. The median follow-up time was 37 months (range: 6-210) for the entire group. The 3-year overall survival (OS) for RIC and MAC patients was 67% and 60%, respectively (p>0.05). The 3-year progression-free survival (PFS) for RIC and MAC patients was 88% and 77%. In multivariate analysis, the type of conditioning regimen (RIC vs. MAC) did not influence PFS (p=0.24). Acute graft-versus-host disease (GVHD) was seen in five of the RIC patients and 9 of the MAC patients. Chronic GVHD was seen in 16 of the RIC patients and 6 of the MAC patients. There was no significant difference between the two groups in terms of acute GVHD (p=0.089), but there was a significant difference between the two groups in terms of chronic GVHD (p=0.03). Conclusion: This retrospective analysis confirmed that MAC and RIC regimens had a consistently equivalent rate of OS and PFS in AML patients who underwent allo-HSCT. The choice of MAC versus RIC conditioning regimen might be decided on the basis of patient and disease characteristics.
dc.language.isoen
dc.relation.isversionof10.4274/tjh.galenos.2019.2018.0220
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleComparison Of Myeloablative Versus Reduced-Intensity Conditioning Regimens For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia: A Cohort Study
dc.title.alternativeComparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkish Journal Of Hematology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume36
dc.identifier.issue2
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States